ArticlePharmaceutical research2017
Post-Synthetic Modification Nanoscale Metal-Organic Frameworks for Targeted Drug Delivery in Cancer Cells.
Article in Pharmaceutical research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 48 citations in OpenAlex.
- Cu-based metal-organic frameworks: synthesis, biomedical applications, and beyond.Discover nano · 2026Review
- Recent advances and potential applications for metal-organic framework (MOFs) and MOFs-derived materials: Characterizations and antimicrobial activities.Biotechnology reports (Amsterdam, Netherlands) · 2024Review
- A reliable QSPR model for predicting drug release rate from metal-organic frameworks: a simple and robust drug delivery approach.RSC advances · 2023Article
- Applications of Metal-Organic Frameworks as Drug Delivery Systems.International journal of molecular sciences · 2022Review
- The emergence of nanoporous materials in lung cancer therapy.Science and technology of advanced materials · 2022Review
- Enhanced Antibacterial Potential of Amoxicillin againstAntibiotics (Basel, Switzerland) · 2021Article
- Functional Nucleic Acid Nanomaterials: Development, Properties, and Applications.Angewandte Chemie (International ed. in English) · 2021Review
- Metal-Organic Frameworks and Their Composites Towards Biomedical Applications.Frontiers in molecular biosciences · 2021Review
- Synthesis and modification of ZIF-8 and its application in drug delivery and tumor therapy.RSC advances · 2020Review
- Design of a Functionalized Metal-Organic Framework System for Enhanced Targeted Delivery to Mitochondria.Journal of the American Chemical Society · 2020Article
- Metal Organic Frameworks as Drug Targeting Delivery Vehicles in the Treatment of Cancer.Pharmaceutics · 2020Review
- Recent developments on zinc(ii) metal-organic framework nanocarriers for physiological pH-responsive drug delivery.MedChemComm · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeMetal-organic frameworks (MOFs) have shown great potentials as drug delivery carriers, but the conventional methods for MOFs synthesis limited their use in biomedicine. The aim of this study was engineered tumor-targeted zinc nanoscale MOFs encapsulating chemotherapy drug.
methodsWe employed post-synthetic modification to construct tumor cell-targeted nanoscale zinc MOFs (nanoMOFs) functionalized with folate as the targeting ligand that binds specifically to folate receptors on tumor cells. The cytoctoxicity of drug-loaded nanoMOFs was measured by MTT assay. The cell target was tested by cell compete assay.
resultsThe successful synthesis of folate-targeted nanoMOFs was confirmed by FTIR,
conclusionsThese results encourage further in vivo studies of this nanoMOFs as candidates for tumor-targeted, sustained-release delivery of chemotherapeutic agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.